Cardiff Oncology Corp - יחס שווי פעילות למכירות CRDF

High R&D costs and dependence on Onvansertib trials create volatility, which is mitigated by partnerships with clinics fighting colorectal cancer. The price-to-sales multiple on the GURU.Markets terminal line chart demonstrates that the current level is 64142.86. This trend reflects joint testing with physicians to implement new therapy standards for colorectal tumors for Cardiff Oncology, Inc. (CRDF).
Cardiff Oncology - פילוחים אנליטיים ומדדי מפתח (CRDF)

This indicator assesses the total enterprise value, including net debt, relative to the volume of generated sales. The metric allows for the identification of overpayment for an asset regardless of its debt load. By analyzing the current EV/Sales level, an investor identifies anomalies in capitalization dynamics. For Cardiff Oncology, Inc. (CRDF), this is critical, as future revenue from targeted drugs depends on insurance reimbursements. The stability of the chart confirms market expectations regarding the commercialization of cancer therapy.